> Detailanzeige

Matulonis, Ursula A.; Walder, Lydia; Nøttrup, Trine J.; Bessette, Paul; Mahner, Sven; Gil-Martin, Marta; Kalbacher, Elsa; Ledermann, Jonathan A.; Wenham, Robert M.; Woie, Kathrine; Lau, Susie; Marmé, Frederik; Casado Herraez, Antonio; Hardy-Bessard, Anne-Claire; Banerjee, Susana; Lindahl, Gabriel; Benigno, Benedict; Buscema, Joseph; Travers, Karin; Guy, Holly; Mirza, Mansoor R.

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial
  • Beteiligte: Matulonis, Ursula A.; Walder, Lydia; Nøttrup, Trine J.; Bessette, Paul; Mahner, Sven; Gil-Martin, Marta; Kalbacher, Elsa; Ledermann, Jonathan A.; Wenham, Robert M.; Woie, Kathrine; Lau, Susie; Marmé, Frederik; Casado Herraez, Antonio; Hardy-Bessard, Anne-Claire; Banerjee, Susana; Lindahl, Gabriel; Benigno, Benedict; Buscema, Joseph; Travers, Karin; Guy, Holly; Mirza, Mansoor R.
  • Erschienen: American Society of Clinical Oncology (ASCO), 2019
  • Erschienen in: Journal of Clinical Oncology
  • Sprache: Englisch
  • DOI: 10.1200/jco.19.00917
  • ISSN: 0732-183X; 1527-7755
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>PURPOSE</jats:title><jats:p> This study estimated time without symptoms or toxicity (TWiST) with niraparib compared with routine surveillance (RS) in the maintenance treatment of patients with recurrent ovarian cancer. </jats:p></jats:sec><jats:sec><jats:title>PATIENTS AND METHODS</jats:title><jats:p> Mean progression-free survival (PFS) was estimated for niraparib and RS by fitting parametric survival distributions to Kaplan-Meier data for 553 patients with recurrent ovarian cancer who were enrolled in the phase III ENGOT-OV16/NOVA trial. Patients were categorized according to the presence or absence of a germline BRCA mutation—g BRCAmut and non-g BRCAmut cohorts. Mean time with toxicity was estimated based on the area under the Kaplan-Meier curve for symptomatic grade 2 or greater fatigue, nausea, and vomiting adverse events (AEs). Time with toxicity was the number of days a patient experienced an AE post–random assignment and before disease progression. TWiST was estimated as the difference between mean PFS and time with toxicity. Uncertainty was explored using alternative PFS estimates and considering all symptomatic grade 2 or greater AEs. </jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p> In the g BRCAmut and non-g BRCAmut cohorts, niraparib treatment resulted in a mean PFS benefit of 3.23 years and 1.44 years, respectively, and a mean time with toxicity of 0.28 years and 0.10 years, respectively, compared with RS. Hence, niraparib treatment resulted in a mean TWiST benefit of 2.95 years and 1.34 years, respectively, compared with RS, which is equivalent to more than four-fold and two-fold increases in mean TWiST between niraparib and RS in the g BRCAmut and non-g BRCAmut cohorts, respectively. This TWiST benefit was consistent across all sensitivity analyses, including modeling PFS over 5-, 10-, and 15-year time horizons. </jats:p></jats:sec><jats:sec><jats:title>CONCLUSION</jats:title><jats:p> Patients who were treated with niraparib compared with RS experienced increased mean TWiST. Thus, patients who were treated with niraparib in the ENGOT-OV16/NOVA trial experienced more time without symptoms or symptomatic toxicities compared with control. </jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang